welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

A safety and efficacy study of ATL1102 in patients with Duchenne muscular dystrophy

key information

study id #: ACTRN12618000970246

condition: Duchenne Muscular Dystrophy

status: completed


Current DMD therapies are aimed at increasing dystrophin levels and reducing inflammation. Improved anti-inflammatory therapies are needed to safely treat this pathology and delay disease progression. This study will be conducted in a single-centre and assess the safety, efficacy and PK of ATL1102 in non-ambulatory patients with DMD.

Read more: ACTRN12618000970246


intervention: ATL1102 (25mg/week)

mechanism of action: Antisense inhibitor to decrease inflammation

last updated: June 11, 2020